Hu Yuhan, Hou Jiangxue, Jiang Zhongxing, Lin Quande
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Exp Hematol Oncol. 2025 Mar 26;14(1):45. doi: 10.1186/s40164-025-00643-6.
Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T resistance, including antigen escape, immunosuppression, and CAR-T cell exhaustion, is essential for enhancing the long-term efficacy of this therapeutic approach. This study provides an in-depth review of the latest findings presented at the 66th ASH Annual Meeting.
嵌合抗原受体T细胞（CAR-T）疗法在多发性骨髓瘤（MM）治疗中显示出巨大潜力。然而，对CAR-T疗法的耐药性仍然是一个关键挑战。研究CAR-T耐药的潜在机制，包括抗原逃逸、免疫抑制和CAR-T细胞耗竭，对于提高这种治疗方法的长期疗效至关重要。本研究深入回顾了在第66届美国血液学会年会上发表的最新研究成果。
